Shares in Evotec AG rose 10 percent Monday on news of a research partnership with Astrazeneca plc on the discovery and development of disease-modifying drugs for chronic kidney disease.
Ablynx NV continues to crank out deals, its latest being a regional accord with Chinese specialty pharma firm Eddingpharm Co. Ltd. to develop and commercialize its anti-RANKL nanobody ALX-0141, for which it is receiving €2 million (US$2.7 million) up front, plus commercial milestones and tiered double-digit royalty payments.
DUBLIN – The University of Limerick (UL) has secured €26.3 million (US$36 million) in philanthropic funding from the Atlantic Philanthropies to anchor a €52 million plan to bolster its research capabilities in pharmaceutical science, biomedical engineering and energy research.
Shares in DBV Technologies SA gained more than 9 percent Friday on news of a licensing deal on a treatment for birch (Betula verrucosa) pollen allergy with Stallergenes SA, which is worth up to €145 million (US$198 million) in milestone payments, as well as royalties on potential product sales.
Shares in DBV Technologies SA gained more than 9 percent Friday on news of a licensing deal on a treatment for birch (Betula verrucosa) pollen allergy with Stallergenes SA, which is worth up to €145 million (US$198 million) in milestone payments, as well as royalties on potential product sales.
Ablynx NV continues to crank out deals, its latest being a regional accord with Chinese specialty pharma firm Eddingpharm Co. Ltd. to develop and commercialize its anti-RANKL nanobody ALX-0141, for which it is receiving €2 million (US$2.7 million) up front, plus commercial milestones and tiered double-digit royalty payments.
DUBLIN – The University of Limerick (UL) has secured €26.3 million (US$36 million) in philanthropic funding from the Atlantic Philanthropies to anchor a €52 million plan to bolster its research capabilities in pharmaceutical science, biomedical engineering and energy research.
Shares in Prosensa Holding NV plunged 70.3 percent last Friday on news that its exon-skipping antisense drug drisapersen failed to meet the primary endpoint of a Phase III trial in Duchenne muscular dystrophy (DMD).
Morphosys AG raised €84 million (US$114 million) in a private placement, adding another hefty chunk of change to what is already a robust balance sheet.
A consortium led by the Royal College of Surgeons in Ireland (RCSI) has secured €11.5 million (US$15.4 million) in funding from the European Commission (EC) to build a comprehensive picture of microRNA (miRNA) biology in patients with epilepsy.
